Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of CAPRELSA is substantial. |
Clinical Added Value
| minor |
The transparency Commission considers that CAPRELSA provides a minor improvement in the actual benefit (IAB level IV) in the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
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
mwnesXgjCwHE3h7c
Listen
